Acute kidney injury (AKI) and chronic kidney disease (CKD) are common in patients awaiting liver transplantation, and both have a marked impact on the perioperative and long-term morbidity and mortality of liver transplant recipients. Therefore, we review the epidemiology of 
 HRS-AKI is a subset of AKI in patients with cirrhosis. 1B  More than half of patients with decompensated cirrhosis have at least some degree of kidney dysfunction. 1C
Prevention of AKI
Prevention of AKI is critical since it is associated with increased mortality in patients with cirrhosis (25) and is one of the most powerful predictors of post-LT survival. There are several, often co-existent, physiologic and clinical insults that can negatively impact kidney function ( Table 2) This article is protected by copyright. All rights reserved.
vancomycin, amphotericin B); 2) allergic interstitial injury [e.g. non-steroidal anti-inflammatory drugs (NSAIDs), beta-lactam antibiotics, diuretics]; and 3) intra-kidney blood flow impairment (e.g radiocontrast dye, NSAIDs, renin-angiotensin-aldosterone system blockers)(38). In addition, changes in drug distribution due to volume overload and portal hypertension and altered pharmacokinetics due to changes in kidney and hepatic blood flow and function can clinically significantly modulate the concentration and half-life of medications and their metabolites.
Key Points and Recommendations:
 AKI is best prevented in cirrhotic patients through utilization of SBP prophylaxis, IV albumin use in patients with SBP, antibiotic prophylaxis for gastrointestinal bleeding, and simultaneous administration of IV albumin with large volume paracentesis. 1A
Management of AKI
Diagnosing the etiology of AKI is critical in determining therapy (Figure 1) . Regardless of the AKI etiology, removing potential precipitating factors such as diuretics and optimizing volume status, should be initiated even before a cause of AKI is established (Table 3) . Intravascular volume expansion is an important part of treatment but also part of establishing the AKI etiology. Patients in whom other causes of AKI have been ruled out should receive treatment for HRS with vasoconstrictors in combination with IV albumin (Table 3 )(39-57).
Meta-analyses have shown a correlation between vasoconstrictor therapy increasing mean arterial pressure (MAP), improvement in kidney function, and short-term survival benefit irrespective of the agent used (58, 59). Terlipressin is the most extensively studied and documented first-line therapy for HRS-AKI in countries with access. However, due to the unavailability of terlipressin in North America, midodrine in combination with octreotide (39,
This article is protected by copyright. All rights reserved. (Table 4) . Unlike midodrine/octerotide (56), norepinephrine has been shown to be equivalent to terlipressin, although the expense of norepinephrine use, need for ICU monitoring, and the inferior quality of data continue to support terlipressin as the agent of choice in areas with access (60) . The optimal duration of medical treatment is not well established, however in patients who failed to demonstrate improvement in Scr after day 4 are less likely to have HRS reversal (61) and an indication for treatment beyond 14 days has not been established. Increase in MAP ≥5 mmHg during treatment, baseline Scr <3 mg/dL, Child-Pugh score <13, lower MELD score, younger age, and bilirubin <10 mg/dL, have all been shown to be independent predictors of therapeutic response.
Of note, recent data has compared infusion to bolus therapy with terlipressin and shown similar responses to both regimens with fewer side effects and a lower total daily dose needed in those receiving infusional therapy (62) . Ideally those patients with response to therapy would be given priority for transplant to avoid the need for SLKT (63) .
Transjugular intrahepatic portosystemic shunt (TIPS) has been shown to improve kidney function in small studies of patients with HRS (64) (65) (66) . However, TIPS is contraindicated in patients with severe hepatic dysfunction, defined as serum bilirubin >5 mg/dL, a high MELD score, significant kidney dysfunction, cardiac failure or clinically significant hepatic encephalopathy.
The initiation of RRT should be made on clinical grounds, including hyperkalemia, oliguria with volume overload, metabolic acidosis, refractory hyponatremia not responding to medical management, and diuretic resistance/intolerance. Optimal timing for RRT indication has not been studied in patients with cirrhosis; however, data from AKI studies in critically ill patients without liver disease suggests that early RRT initiation and maintenance of negative fluid balance in those with volume overload may improve survival (67) (68) (69) (70) (71) . In patients receiving RRT, continuous RRT allows for the slower correction of serum sodium and provides greater cardiovascular stability compared to standard hemodialysis (72, 73) .
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Although initial small studies on albumin dialysis using the Molecular Adsorbent Recirculating System (MARS) documented a survival benefit compared to standard medical therapy (74) , a more recent multicenter study (RELIEF trial) failed to reproduce this benefit at 28-days, despite biochemical improvement (75) . to be 18% and 25%, respectively (76) . Although these high rates may be partially attributable to long-term calcineurin inhibitor (CNI) use, diabetes and hypertension (reviewed elsewhere), the most important predictor of CKD post-LT is pre-transplant kidney function. The development and duration of AKI pre-transplant not only reduces post-LT kidney function long-term but also increases mortality (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) . Reversal of HRS-1 with vasoconstrictors pre-LT has been associated with improved post-LT outcomes (8, 87, 88) . At the present time, specific pre-LT predictors of CKD development post-LT are lacking. Table 3 .
Key Points and

Key Points and Recommendations see
Evolution in the Composition of the Liver Transplant Waitlist
The composition of the LT waitlist in the United States (US) and Europe is being transformed by three events that are increasing the rate of pre-transplant and post-transplant AKI and CKD. First is the decades-long obesity epidemic, with resulting parallel increase in the
prevalence of non-alcoholic steatohepatitis (NASH). Second is the development of highly effective and well-tolerated direct acting antiviral (DAA) agents for hepatitis C virus (HCV) infection. Third is adoption of the MELD score, which includes Scr as the most heavily weighted value in MELD based organ allocation.
In addition to the contribution of ESLD to kidney dysfunction, some causes of cirrhosis have disease specific kidney injury mechanisms. Hepatitis C virus (HCV), for example, is associated with membranoproliferative glomerulonephritis and type 2 cryoglobulinemia.
Reversal of kidney dysfunction is not an inevitable consequence of HCV eradication, even for cryoglobulinemia (89) . Similar to HCV infection, NASH is independently associated with CKD (90, 91) , and alcoholic liver disease, which is associated with IgA nephropathy.
Liver disease secondary to HCV infection continues to be the most common indication for LT, affecting ~one third of LT recipients (92) . NASH is the third most common indication for LT in the US and the second most common reason for being waitlisted (93) . Although this may still be an underestimate of NASH frequency, since it does not account for the likely high prevalence of NASH among the 10% of recipients with "cryptogenic" cirrhosis (93) .
Although the number of patients with HCV infection in need of LT is projected to rise in the coming decade (92) , the rate of increase is a small fraction of that occurring for NASH (93) .
The frequency of HCV patients needing LT will also be affected by the advent of well-tolerated DAAs; recent clinical trials of DAAs have demonstrated safety and efficacy even in patients with decompensated cirrhosis (94) . In addition, HCV viremia has been associated with an increased risk of CKD and ESRD (95) ; although data are lacking, one would expect improved renal outcomes after virologic cure.
Based on these well-established trends in the US LT waitlist composition, it is highly probable that NASH and HCV will comprise well over half of transplant activity for at least the next decade. Although the association of NASH with pre-and post-LT CKD is likely related to the relatively high prevalence of diabetes and hypertension, NASH is predictive of CKD independent
of other factors (90, 96) . As both of these diseases are independently predictive of pre-and post-LT CKD, the rise in NASH frequency and the continued high prevalence of HCV as top indications for LT will almost certainly result in increased rates of CKD pre-and post-LT.
Implications of AKI Etiology on Mortality Risk of MELD Score
The near ubiquitous presence of kidney hypoperfusion/ischemia in cirrhosis, with subsequent low fractional excretion of sodium, can make the diagnosis of ATN difficult.
Robust data regarding the reversibility of AKI in patients with cirrhosis were generated in a prospective study of 562 patients with cirrhosis and AKI (97) . The authors observed that HRS was less common than prerenal or infection-associated kidney injury. Of the nearly 500 patients in whom a diagnosis could be made, the most common precipitating causes of AKI were: infection (46%), prerenal (32%), HRS (13%), and parenchymal (9%) kidney disease.
Approximately 80% of AKI in patients with cirrhosis is secondary to a treatable precipitating cause, and it has been estimated that 10-20% of patients with cirrhosis who develop AKI have an element of ATN.
The curvilinear association with increasing MELD score and waitlist mortality, coupled with the direct relationship of MELD score with likelihood of undergoing LT, raises the possibility that treating AKI in patients on the waitlist may improve short-term mortality but decrease the short-term likelihood of LT. The net effect of longer waitlist time, with associated increased waitlist mortality, together with longer duration of kidney dysfunction is difficult to calculate and has not been modelled. Perhaps in part for this reason, survival following HRS is primarily dependent on reversal of hepatic failure with less significant survival improvement following HRS reversal (52, 98). Instead, treating AKI, other than HRS-1, in waitlisted patients presumes reversibility of AKI and a net benefit of successful treatment.
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When weighing the relative merits of a specific organ offer, it is important to consider that a MELD score contributed to by AKI differentially impacts 90-day mortality dependent on the AKI etiology (97) . Differential weighting of Scr according to AKI etiology could, in theory, be utilized to reduce waitlist mortality, which might be accomplished by utilizing delta Scr instead of absolute Scr values (99) . 
Key Points and Recommendations
Considerations for SLKT
Since the introduction of the MELD score to assign priority for donor allocation, the proportion of LT recipients that undergo simultaneous liver-kidney transplantation (SLKT) has tripled.(http://srtr.transplant.hrsa.gov/annual_reports/) The increase in SLKT frequency is a reflection of: 1) the increasing frequency of ESRD among LT recipients and 2) the high priority for LT assigned to patients with kidney dysfunction. In addition to MELD based allocation increasing the risk for AKI and CKD pre-LT, the MELD at transplant is increasing nationwide (93) . As a result, kidney dysfunction has almost become a requirement for patients to advance to the top of waitlist (100) . Thus, at the time of LT, a high percentage of ESLD patients have significant AKI with or without CKD with variable improvement after LT (77, (101) (102) (103) (104) (105) . It is well known that recipients with AKI that results in prolonged dialysis post-LT have reduced survival (106) . It is therefore no surprise that SLKT utilization has increased (107) . This would be acceptable if kidney allografts were readily available, but there is already a severe kidney
allograft shortage for patients with isolated ESRD who also have high waitlist mortality.
Furthermore, the addition of a kidney transplant to the LT procedure adds significant operative time, potential morbidity, and marked cost.
Ideally, patients with HRS-AKI with a favourable response to vasoconstrictor therapy and intravenous albumin would receive prioritization for transplant with a liver only to facilitate a single organ transplant before irreversible kidney dysfunction occurred (63) .
Alternatively, MELD coefficients could be changed to decrease the weight of kidney dysfunction in the MELD score. However, because changes to MELD have proven difficult, the creation of stringent criteria to access SLKT has been proposed. In 2008, a United Network for Organ Sharing (UNOS) consensus conference evaluated allocation of kidneys to LT candidates with kidney dysfunction (108) . Several agreed-upon parameters predicting non-recovery of native kidney function post-LT included (108): 1) CKD with estimated (MDRD equation) GFR ≤30 mL/min; 2) CKD on kidney biopsy (defined as >30% glomerulosclerosis and/or 30% fibrosis);
3) AKI with Scr ≥2.0 mg/dL and dialysis ≥8 weeks; 4) special consideration to patients with comorbidities (e.g. hypertension and diabetes) and to patients >65 years old; and 5) metabolic kidney disease (e.g. hyperoxaluria, atypical haemolytic uremic syndrome, methylmalonic aciduria). Conversely, not meeting these UNOS criteria implies an expectation of native kidney function recovery to acceptable levels after LT alone. However, the UNOS criteria are not official Organ Procurement and Transplantation Network (OPTN) policy, and as a result the current allocation system allows listing for SLKT based on subjective clinical judgment, with the UNOS criteria serving as a guideline. A recent survey of US transplant centers showed that AKI leading to dialysis for a minimum of 4 weeks and CKD (defined mainly by GFR<30 mL/min) were minimum criteria used by most centers to recommend SLKT (109). However, because adherence to this guidance is not mandatory, SLKT selection criteria continue to vary dramatically across the United States (109) . Unfortunately, neither center nor national
guidelines predict kidney recovery with a high level of certainty (77, 108, 110, 111) . Other predictors, such as kidney ultrasound, measured GFR (iothalamate, iohexol) and kidney biopsy, may be too subjective, inaccurate, invasive, and costly for universal clinical implementation for SLKT selection.
Ultimately, dissemination of appropriate, mandatory selection strategies is needed.
Recently, the OPTN/UNOS Kidney Transplantation Committee in collaboration with the Liver Intestine Transplant Committee proposed more specific SLKT medical eligibility criteria with a safety net for LT only allograft recipients with a continued need for kidney transplantation.
Specifically, pre-LT patients with CKD would need documentation of dialysis or GFR ≤35 mL/min, and patients with AKI would need GFR ≤25 mL/min for ≥6 consecutive weeks prior to SLKT listing (112) . For patients who do not meet these criteria but have non-recovery of kidney function post-LT alone, kidney transplant waitlist prioritization has been proposed.
Prioritization would occur after OPTN review verifies GFR ≤20 mL/min or continued dialysis 60-365 days post-LT. If accepted, these criteria will provide greater stringency for SLKT allocation and will facilitate kidney transplant in LT recipients with persistent kidney dysfunction after liver only transplantation. Fortunately, a similar policy supporting stringent criteria for SLKT allocation and the potential for a safety net of kidney allograft allocation in LT recipients without renal recovery has been proposed in Canada (113) .
Even with specific clinical criteria for SLKT allocation, pre-operative biomarker assessment would ideally allow more accurate kidney allograft allocation (Table 5 ) (110) .
Recent data has demonstrated that biomarkers can more appropriately classify, quantitate, and prognosticate kidney dysfunction (18, 114, 115) . The majority of these markers, such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL), are elevated in acute tubular injury, contrast nephrotoxicity, or peri-operative kidney injury but may also be markers of kidney disease progression (116) . Pre-LT other plasma protein profiles This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. between 3 and 12 months post-LT was associated with increased mortality (OR=2.6; p<0.001) (118) . In a separate study, a GFR of 15-29 mL/min had a HR= 2.7 (p<0.01), and a GFR <15 mL/min had a HR=5.5 (p<0.01) (119) On the policy level, the best information must shape future allocation decisions. SLKT utilization and equitable/appropriate access to kidney transplantation via a 'safety net' is likely to remain contentious but a consensus is urgently needed. In order to maximize post-LT survival outcome, an optimal policy regarding SLKT would aim for a post-LT GFR target of >60 mL/min in the maximum number of organ recipients. In addition, introduction of novel therapeutic agents would require adaptation of the organ allocation policy. For example, while future therapy for HRS may restore Scr, whether the corresponding reduction in the MELD score is commensurate with mortality benefits, based on the kidney functional recovery must be studied. Ultimately, promoting timely organ allocation and preventing pre-and postoperative morbidity and mortality would require prospective multicentre data collaborations and accurate risk assessment tools to inform data-driven interventions and rational policy development addressing all stakeholders in LT.
guide.medlive.cn This article is protected by copyright. All rights reserved.
Supporting Information
Additional Supporting Information may be found in the online version of this article 
23.
Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. Oliguria is an early predictor of higher mortality in critically ill patients. Kidney international. 2011;80 (7):760-7.
24.
Macedo E, Malhotra R, Claure-Del Granado R, Fedullo P, Mehta RL. Defining urine output criterion for acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2011;26(2):509-15. This article is protected by copyright. All rights reserved. 
Risk Factors Preventive Strategies
Hepatorenal syndrome development Antibiotic prophylaxis following GI bleeding x 7 days. 1A This article is protected by copyright. All rights reserved. 
Treatment of HRS1
Terlipressin* Vasopressin analogue  HRS1 patients need resuscitation with IV albumin (initially 1 g albumin/kg for two days, up to a maximum of 100 g/day, followed by 20 to 40 g/day) in combination with a vasoconstrictor (1A), preferentially terlipressin. 1A 0.5-1.0 mg q4-6h, increased on day 4-2 mg IV q4-6 h**, if Scr has not decreased by >30% from baseline following fluid recessitation In countries where terlipressin is not available, norepinephrine can be used as an initial therapy in ICU patients or as an alternative in patients in whom midodrine + octreotide has failed. 1C 
